mesa 1.5. dr joan valldeperas
TRANSCRIPT
![Page 1: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/1.jpg)
Hospital Universitario de Bellvitge.L’Hospitalet de Llobregat (Barcelona)
Dr. Joan Valldeperas
![Page 2: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/2.jpg)
[ERS] The healthcare burden of non-compliance to pharmacotherapeutic escalation
recommendations for COPD
Tavares R, Zhang S, Dang-Tan T, Ismaila A, Stutz M, Coletta N, et al.
Mesa 1
![Page 3: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/3.jpg)
![Page 4: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/4.jpg)
To describe the healthcare burden associated with not escalating patients with COPD managed with LAMA or LABA monotherapy or LAMA/LABA dual therapy to ICS/LAMA/LABA following a moderate or severe exacerbation.
This observational study utilised medical claims from the Quebec Provincial Health Insurance administrative database.
Included were patients ≥40 years of age with an incident diagnosis of COPD (during 2002–2011) receiving a respiratory medicine within 2 weeks of a COPD claim and treated with a LAMA, LABA or LAMA/LABA without a preceding moderate or severe exacerbation in 2 years preciding.
The study cohort were followed for a median of 3.56 years after the first exacerbation.
Multivariate-adjusted outcomes included incidence density rates for moderate or severe COPD exacerbations and healthcare utilisation, stratified by escalation to ICS/LAMA/LABA triple therapy following an exacerbation.
.
![Page 5: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/5.jpg)
Tasa de densidad de incidencia
![Page 6: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/6.jpg)
Overall, 19,198 (49.5%) patients experienced COPD exacerbations. Of these, 1,136 (5.9%) were escalated to triple therapy following an exacerbation. Compared with patients switched to triple therapy, those not escalated experienced increased mean incidence density rates (per 100 person-years) for future exacerbations (any: 0.21 vs 0.18, p<0.001; moderate: 0.10 vs 0.07, p<0.001), ER visits (0.11 vs 0.10, p<0.05), and greater use of antibiotics, oral corticosteroids and rescue medications (0.94 vs 0.79, 0.76 vs 0.66, 1.08 vs 0.50; p<0.001). Hospitalisation rates were similar among patients treated with triple therapy. Other outcomes were similar between groups.
.
![Page 7: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/7.jpg)
Failure to escalate to ICS/LAMA/LABA triple therapy following an exacerbation results in increased exacerbations, ER visits and concomitant medication use in patients with COPD.
Funded by GSK: HO-13-14097.
![Page 8: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/8.jpg)
[ERS] The healthcare burden of non-compliance to pharmacotherapeutic escalation
recommendations for COPD
Rivera-Ortega P, González J, Restituto P, Varo N, Colina I, et al.
Mesa 1
![Page 9: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/9.jpg)
Smoking Definitions Never Smokers – Adults who have never smoked a cigarette or who smoked fewer than 100 cigarettes in their entire lifetime.Former Smokers – Adults who have smoked at least 100 cigarettes in their lifetime, but say they currently do not smoke.Nonsmokers – Adults who currently do not smoke cigarettes, including both former smokers and never smokers.Current Smokers – Adults who have smoked 100 cigarettes in their lifetime and currently smoke cigarettes every day (daily) or some days (nondaily).
![Page 10: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/10.jpg)
![Page 11: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/11.jpg)
![Page 12: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/12.jpg)
![Page 13: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/13.jpg)
![Page 14: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/14.jpg)
![Page 15: Mesa 1.5. Dr Joan Valldeperas](https://reader036.vdocuments.mx/reader036/viewer/2022070514/5880a83b1a28abf32c8b4893/html5/thumbnails/15.jpg)